Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers

David A. Sack, R. Bradley Sack, Janet Shimko, George Gomes, Donna O'Sullivan, Karen Metcalfe, Dale Spriggs

Research output: Contribution to journalArticlepeer-review


A new live oral cholera vaccine, Peru-15, was studied for safety, immunogenicity, and excretion in 2 groups of healthy volunteers. Twelve inpatient volunteers received freshly harvested vaccine in doses of either 107 or 109 cfu. Subsequently 50 outpatient volunteers received freeze- dried vaccine in doses of 108 or 109 cfu or placebo in a three-cell, double-masked, placebo-controlled trial. The strain was well tolerated at all dose levels, and it stimulated high levels of vibriocidal antibodies in most inpatient volunteers and in all outpatient volunteers. Although antitoxin responses were less frequent and of lower magnitude than the vibriocidal responses, antitoxin responses were seen in >60% of the outpatient volunteers. About 60% of the volunteers excreted the vaccine in their feces; however, fecal excretion did not correlate with serologic responses. It is concluded that Peru-15 is a safe and immunogenic oral vaccine for cholera.

Original languageEnglish (US)
Pages (from-to)201-205
Number of pages5
JournalJournal of Infectious Diseases
Issue number1
StatePublished - 1997

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers'. Together they form a unique fingerprint.

Cite this